Showing results (141-150 of 185) with videos related to

Sort By:
Pageof 19
Blood|August 24, 2012
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesMikkael A Sekeres, Ramon V Tiu, Rami Komrokji, et al.
Blood Advances|July 15, 2022
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemiaLori Muffly, Jun Yin, Sawyer Jacobson, et al.
Leukemia|November 7, 2017
Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodineR J Molenaar, C Pleyer, T Radivoyevitch, et al.
Blood Advances|November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Blood Advances|October 21, 2022
The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 studyIbrahim Aldoss, Jun Yin, Anna Wall, et al.
Leukemia & Lymphoma|April 9, 2025
Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary centerMeera Patel, Emily C Zabor, Ahmed Mohamed, et al.
Leukemia|September 19, 2013
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasmsF Traina, V Visconte, P Elson, et al.
The Lancet. Haematology|July 9, 2017
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Anjali S Advani, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 11, 2025
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary CenterAhmed Mohamed, Emily C Zabor, Meera Patel, et al.
Blood|July 27, 2018
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLAmir T Fathi, Harry P Erba, Jeffrey E Lancet, et al.
Pageof 19